


### COVID-19 IMPACT

This report has been affected by the COVID-19 pandemic. All forecasts and analysis have been revised to reflect the current view including the effect of the pandemic and associated recession.

# RESEARCH REPORT



## WHOLE GENOME and EXOME SEQUENCING MARKETS

By Research, Clinical, Tumor, Pathogen, AgriBio & Consumer with Executive and Consultant Guides.

(Including the Whole Genome Sequence of SARS-CoV-2)

2021 to 2025





Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the X-Ray market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

- i. Whole Genome Sequencing Market - Strategic Situation Analysis & COVID Impact ..19
- ii. Guide for Executives, Marketing, Sales and Business Development Staff .....21
- iii. Guide for Management Consultants and Investment Advisors .....23
- 1. Introduction and Market Definition .....25
  - 1.1 Whole Genome Sequencing Definition In This Report..... 26
    - 1.1.1 Whole and Exome Sequencing ..... 26
    - 1.1.2 Research and Clinical..... 27
    - 1.1.3 Clinical Tumor ..... 27
    - 1.1.4 Clinical Pathogen..... 27
    - 1.1.5 Agri/Other ..... 27
    - 1.1.6 Direct to Consumer ..... 27
  - 1.2 The Genomics Revolution ..... 28
  - 1.3 Market Definition ..... 30
    - 1.3.1 Revenue Market Size..... 30
  - 1.4 U.S. Medical Market and laboratory Testing - Perspective ..... 32
    - 1.4.1 U.S. Medicare Expenditures for laboratory testing ..... 32
  - 1.5 Sizing the Genome – Not What You Think ..... 34
    - 1.5.1 Cost, Price and Genome Size, Pricing Practice ..... 35
- 1A GLOBAL LISTING OF HIGH THROUGHPUT SEQUENCING ESTABLISHMENTS INSTALLED  
BASE – Location & Contacts .....36
- 2. Market Overview ..... 122
  - 2.1 Market Participants Play Different Roles ..... 123
    - 2.1.1 Instrument Manufacturer ..... 124
    - 2.1.2 Independent lab specialized/esoteric ..... 124

- 2.1.3 Independent lab national/regional..... 124
- 2.1.4 Independent lab analytical ..... 125
- 2.1.5 Public National/regional lab ..... 125
- 2.1.6 Hospital lab ..... 125
- 2.1.7 Physician lab ..... 126
- 2.1.8 DTC Lab..... 126
- 2.1.9 Sequencing Labs ..... 126
- 2.1.10 Audit body ..... 127
- 2.2 Whole Genome Sequencing –Markets, Examples and Discussion..... 128
  - 2.2.1 Direct to Consumer – Two Approaches ..... 128
    - 2.2.1.1 The New Age of Medical Information ..... 128
    - 2.2.1.2 Dangers in DTC-WGS – Health Costs and Regulation ..... 129
    - 2.2.1.3 Newborn and Prenatal – A Brave New World ..... 130
    - 2.2.1.4 DTC – How Many Segments? ..... 130
  - 2.2.2 Research Markets ..... 136
    - 2.2.2.1 Research Funding and Capital Expense ..... 136
    - 2.2.2.2 WGS Datasets Preferred ..... 136
    - 2.2.2.3 Existing research repurposed ..... 136
    - 2.2.2.4 Organism Wide Market ..... 137
    - 2.2.2.5 Service Suppliers Respond ..... 137
  - 2.2.3 Clinical – Understanding Germline and Somatic ..... 138
    - 2.2.3.1 Somatic – Chasing Mutations and Pharmacogenomics ..... 138
  - 2.2.4 Pathogen Testing ..... 139
    - 2.2.4.1 The Hepatitis C Story ..... 139
    - 2.2.4.2 Will the Microbiology Department Disappear? ..... 140
  - 2.2.5 AgriBio – Big Business ..... 141
    - 2.2.5.1 GMO is Here to Stay ..... 141

- 2.2.5.2 WGS Benefits and Risks..... 142
- 2.2.5.3 The New Agriculture ..... 142
- 2.3 Industry Structure ..... 144
  - 2.3.1 Hospital's Testing Share ..... 144
  - 2.3.2 Economies of Scale ..... 144
  - 2.3.3 Instrument Manufacturer Role..... 144
  - 2.3.4 Healthcare Industry Impacts – Still Struggling..... 145
    - 2.3.4.1 Can the Healthcare Industry Adapt?..... 145
    - 2.3.4.2 Genetic Counselling as an Industry ..... 146
    - 2.3.4.3 WGES Adoption and Cannibalization ..... 146
    - 2.3.4.4 The Meaning of Grail..... 147
- 3. Market Trends..... 148
  - 3.1 Factors Driving Growth..... 149
    - 3.1.1 Diagnostic Factors..... 149
    - 3.1.2 Interpreting the Code Otherwise ..... 150
    - 3.1.3 Changes in Agriculture ..... 150
    - 3.1.4 Fertility Technology Comes of Age ..... 150
    - 3.1.5 Pathogen Challenges ..... 150
  - 3.2 Factors Limiting Growth..... 151
    - 3.2.1 Increased Competition Lowers Price..... 151
    - 3.2.2 Lower Costs..... 152
    - 3.2.3 Healthcare Cost Concerns Curtail Growth ..... 153
    - 3.2.4 Wellness has a downside ..... 153
    - 3.2.5 GMO Opposition Movement ..... 153
  - 3.3 Sequencing Instrumentation ..... 154
    - 3.3.1 Instrumentation Tenacity ..... 154
    - 3.3.2 Declining Cost Changes Industry Structure ..... 154

- 3.3.3 LISTING of CURRENT NGS INSTRUMENT SPECIFICATIONS ..... 155
- 3.3.4 Illumina ..... 157
- 3.3.5 ION..... 157
- 3.3.6 Pacific Biosystems..... 158
- 3.3.7 Roche 454 ..... 158
- 3.3.8 SOLiD ..... 158
- 3.3.9 Oxford Nanopore ..... 158
  - 3.3.9.1 What is Oxford Nanopore Sequencing? ..... 158
  - 3.3.9.2 What can Oxford Nanopore Sequencingt be used for? ..... 159
  - 3.3.9.3 Oxford Nanopore Products ..... 159
- 3.3.10 Long Reads – Further Segmentation..... 160
- 3.3.11 Linked Reads..... 160
- 3.3.12 Targeted Sequencing Adopts CRISPR ..... 160
- 3.3.13 New Sequencing Technologies ..... 161
  - 3.3.13.1 RNAP sequencing..... 161
  - 3.3.13.2 In vitro virus high-throughput sequencing ..... 162
  - 3.3.13.3 Tunnelling currents DNA sequencing..... 162
  - 3.3.13.4 Sequencing by hybridization..... 162
  - 3.3.13.5 Sequencing with mass spectrometry..... 163
  - 3.3.13.6 Microfluidic Sanger sequencing ..... 163
  - 3.3.13.7 Microscopy-based techniques ..... 164
- 4. WGES Recent Developments ..... 165
  - 4.1 Recent Developments – Importance and How to Use This Section ..... 166
    - 4.1.1 Importance of These Developments ..... 166
    - 4.1.2 How to Use This Section..... 166
  - Whole-Genome Sequencing Aids Diagnosis in Stockholm..... 166
  - Variantx Raises \$20M in Series C Financing ..... 168

Nonacus Whole-Genome Sequencing Service for SARS-CoV-2 Testing Laboratories ..... 168

German Center to Report Polygenic Risk Scores in Clinical Whole-Genome Testing ..... 169

Stanford Launches Clinical Whole-Genome Sequencing for Cardiovascular Testing ..... 171

Illumina and New York Healthcare Providers Partner on Clinical WGS..... 176

Increased Adoption of WGS Needs Acceptance by Payors, Providers..... 177

Veritas Intercontinental Completes €5M Series B Financing Round..... 180

M2GEN and Discovery Life Sciences Enter into Agreement for Bioinformatics Support Services ..... 181

Genomics England Adopts Quantum ActiveScale Object Storage ..... 182

GenomiQa, Icon Group to Validate Genomic Analysis Platform CapeDx..... 184

NHS Wales Introduces Whole-Genome Sequencing for Critically Ill Newborns ..... 185

Illumina Achieves First FDA EAU for NGS-Based SARS-CoV-2 Test..... 187

C2i Genomics to Launch Trials for MRD Detection Tech..... 188

Roche Acquires Sequencing Company Stratos Genomics..... 190

UK COVID-19 Sequencing Consortium Launches With £20M in Government, Wellcome Trust Funding..... 191

Invitae Acquires Three Companies: YouScript, Genelex, Diploid..... 192

Experience From Centralized Genomic Medicine Lab..... 194

MGI to Enable \$100 Human Genome ..... 198

Nebula Genomics offers \$299 WGS ..... 200

Team to Study Campylobacter Omics..... 201

Veritas Genetics Restarts US Business ..... 202

NEOGEN, Gencove partner to advance animal genomics ..... 203

UK Whole-Genome Sequencing Project Obtains £200M..... 204

WGS may help with disease outbreaks ..... 205

Veritas Cuts WGS Price by 40%..... 206

Dante Labs Launches GenomeL, Long Reads Human Whole Genome Sequencing ..... 207

Machine-learning system used to diagnose genetic diseases ..... 208



Whole Genome Sequencing for healthy creates controversy ..... 210

100,000 whole genomes sequenced in the NHS ..... 213

Nebula Genomics Offers FREE Whole Genome Sequencing ..... 213

5. Profiles of Key Companies .....216

10x Genomics, Inc..... 217

23andME Inc..... 218

Abbott Diagnostics..... 220

AccuraGen Inc..... 222

Adaptive Biotechnologies ..... 223

Admera Health, LLC..... 224

Agena Bioscience, Inc..... 225

Agilent ..... 227

Akonni Biosystems..... 229

Ancestry.com LLC ..... 230

Anchor Dx ..... 232

ArcherDx, Inc. .... 233

ARUP Laboratories ..... 234

Asuragen..... 236

Baylor Miraca Genetics Laboratories ..... 238

Beckman Coulter Diagnostics ..... 239

Becton, Dickinson and Company..... 240

BGI Genomics Co. Ltd ..... 242

Bioarray Genetics ..... 244

Biocept, Inc..... 245

Biodesix Inc. .... 246

BioFluidica ..... 247

BioGenex..... 248

Biolidics Ltd..... 250

bioMérieux Diagnostics..... 251

Bioneer Corporation..... 253

Bio-Rad Laboratories, Inc..... 255

Bio-Techne ..... 257

C2i Genomics ..... 259

Cancer Genetics..... 260

Caris Molecular Diagnostics ..... 262

CellMax Life..... 263

Centogene ..... 264

Chronix Biomedical ..... 266

Circulogene ..... 267

Clear Labs ..... 268

Clinical Genomics ..... 269

Complete Genomics, Inc. – A BGI Company..... 270

Cynvenio..... 272

Dante Labs..... 273

Datar Cancer Genetics Limited ..... 275

Day Zero Diagnostics ..... 276

Diasorin S.p.A. .... 277

Epic Sciences..... 278

Epigenomics AG..... 279

Eurofins Scientific ..... 280

Excellerate Bioscience ..... 283

Exosome Diagnostics..... 284

Fabric Genomics ..... 286

Fluidigm Corp ..... 287

Freemome ..... 288

FUJIFILM Wako Diagnostics ..... 289

Fujirebio ..... 290

Fulgent Genetics ..... 291

GE Global Research..... 292

GE Healthcare Life Sciences ..... 293

Gencove ..... 295

Genedrive ..... 296

GeneFirst Ltd. .... 297

Genetron Health (Beijing) Co., Ltd..... 298

Genewiz ..... 299

Genomic Health ..... 300

Genomics England..... 302

Genomics Personalized Health (GPH) ..... 304

GenomOncology ..... 306

Genzyme Corporation ..... 307

Grail, Inc. .... 309

Grifols..... 311

Guardant Health ..... 312

Guardiome ..... 313

HeiScreen ..... 315

Helix ..... 317

Helomics..... 319

Hologic ..... 320

Horizon Discovery ..... 322

HTG Molecular Diagnostics..... 324

Human Longevity, Inc. .... 326

iCellate ..... 328

Illumina ..... 329

Incell Dx..... 330

Inivata..... 331

Invitae Corporation ..... 332

Invivoscribe ..... 334

Karius ..... 335

Macrogen ..... 336

MDNA Life SCIENCES, Inc..... 337

MDx Health ..... 338

Medgenome..... 340

Meridian Bioscience ..... 341

Mesa Biotech ..... 343

MIODx..... 344

miR Scientific ..... 345

MNG Labs ..... 346

Molecular MD ..... 347

NantHealth, Inc. .... 348

Natera ..... 350

Nebula Genomics ..... 352

NeoGenomics ..... 353

New Oncology ..... 355

Novogene Bioinformatics Technology Co., Ltd. .... 356

Omega Bioservices ..... 358

OncoDNA..... 360

OpGen ..... 361

ORIG3N, Inc. .... 363

Origene Technologies..... 365

Oxford Nanopore Technologies..... 366

Panagene ..... 367

Perkin Elmer..... 368

Personal Genome Diagnostics..... 370

Personalis..... 371

Precipio ..... 372

PrecisionMed ..... 373

Promega ..... 374

Protagen Diagnostics..... 376

Qiagen Gmbh ..... 377

Quantumdx..... 379

Regeneron ..... 380

Roche Molecular Diagnostics ..... 382

Roswell Biotechnologies..... 384

Seegene..... 385

Sequencing.com..... 387

Siemens Healthineers ..... 389

simfo GmbH ..... 391

Singlera Genomics Inc. .... 392

SkylineDx..... 393

Stratos Genomics ..... 394

Sure Genomics, Inc. .... 395

Sysmex..... 397

Sysmex Inostics..... 399

Tempus Labs, Inc. .... 400

Thermo Fisher Scientific Inc. .... 401

Veritas Genetics ..... 402

Volition..... 404

6. The Global Market for Whole Genome Sequencing .....405

6.1 Global Market Overview by Country ..... 406

6.1.1 Table – Global Market by Country ..... 406

6.1.2 Chart - Global Market by Country ..... 407

6.2 Global Market by Application - Overview ..... 408

6.2.1 Table – Global Market by Application ..... 408

6.2.2 Chart – Global Market by Application – Base/Final Year Comparison ..... 409

6.2.3 Chart – Global Market by Application – Base Year ..... 410

6.2.4 Chart – Global Market by Application – Final Year ..... 411

6.2.5 Chart – Global Market by Application – Share by Year..... 412

6.2.6 Chart – Global Market by Application – Segment Growth ..... 413

6.3 Global Market Organism - Overview ..... 414

6.3.1 Table – Global Market by Organism ..... 414

6.3.2 Chart – Global Market by Organism – Base/Final Year Comparison..... 415

6.3.3 Chart – Global Market by Organism – Base Year ..... 416

6.3.4 Chart – Global Market by Organism – Final Year ..... 417

6.3.5 Chart – Global Market by Organism – Share by Year ..... 418

6.3.6 Chart – Global Market by Organism – Segment Growth..... 419

7. Global Whole Genome Sequencing Markets – By Application .....420

7.1 Research ..... 421

7.1.1 Table Research – by Country ..... 421

7.1.2 Chart - Research Growth..... 422

7.2 Clinical Human ..... 423

7.2.1 Table Clinical Human – by Country ..... 423

7.2.2 Chart - Clinical Human Growth..... 424

- 7.3 Clinical Tumor ..... 425
  - 7.3.1 Table Clinical Tumor – by Country ..... 425
  - 7.3.2 Chart - Clinical Tumor Growth..... 426
- 7.4 Clinical Pathogen..... 427
  - 7.4.1 Table Clinical Pathogen – by Country ..... 427
  - 7.4.2 Chart - Clinical Pathogen Growth ..... 428
- 7.5 Direct to Consumer ..... 429
  - 7.5.1 Table Direct to Consumer – by Country ..... 429
  - 7.5.2 Chart – Direct to Consumer Growth ..... 430
- 7.6 Agriculture/Other ..... 431
  - 7.6.1 Table Agriculture/Other – by Country ..... 431
  - 7.6.2 Chart – Agriculture/Other Growth ..... 432
- 8. Global Whole Genome Sequencing Markets – by Organism .....433
  - 8.1 Human..... 434
    - 8.1.1 Table Human – by Country..... 434
    - 8.1.2 Chart - Human Growth ..... 435
  - 8.2 Pathogen ..... 436
    - 8.2.1 Table Pathogen – by Country ..... 436
    - 8.2.2 Chart - Pathogen Growth..... 437
  - 8.3 Other Organism ..... 438
    - 8.3.1 Table Other Organism – by Country ..... 438
    - 8.3.2 Chart - Other Organism Growth ..... 439
- 9. Vision of the Future of Whole Genome Sequencing .....440
- Appendices .....441
  - I. United States Medicare System: January 2021 laboratory Fees Schedule ..... 441
  - II The Whole Genome Sequence of SARS-CoV-2 ..... 531
  - III Methodology..... 567

II.1 Authors..... 567  
 II.2 Sources ..... 567

Table of Tables

Table 1 The Base Pairs..... 26  
 Table 2 Most Common Traditional Genetic Disorders ..... 28  
 Table 3 Lab Spending 2014 to 2024 ..... 33  
 Table 4 List of GLOBAL SEQUENCING LOCATIONS ..... 37  
 Table 5 Market Players by Type ..... 123  
 Table 6 The Different Markets for Whole Genome Sequencing ..... 128  
 Table 7 DTC Sub Segments ..... 131  
 Table 8 Roles of WGS in AgriBio ..... 141  
 Table 9 The Factors Driving Growth..... 149  
 Table 10 Factors Limiting Growth ..... 151  
 Table 11 - Listing of Current NGS Instrument Specifications ..... 155  
 Table 12 Six New Sequencing Technologies ..... 161  
 Table 13 - Global Market by Region ..... 406  
 Table 14 Global Market by Application..... 408  
 Table 15 Global Market by Organism ..... 414  
 Table 16 Research by Country ..... 421  
 Table 17 Clinical Human by Country ..... 423  
 Table 18 Clinical Tumor by Country..... 425  
 Table 19 Clinical Pathogen by Country ..... 427  
 Table 20 Direct to Consumer by Country ..... 429  
 Table 21 Agriculture/Other by Country ..... 431



Table 22 Human by Country ..... 434

Table 23 Pathogen by Country ..... 436

Table 24 Other Organism by Country ..... 438

Table 25 2021 Clinical Lab Fee Schedule ..... 441

Table of Figures

Figure 1 Clinical Lab Spending 2014 to 2024 ..... 32

Figure 2 Size of Genome for Various Species ..... 34

Figure 3 - Cost To Sequence a Human Genome ..... 152

Figure 4 Base Year Country Market Share Chart ..... 407

Figure 5 Global Market by Application - Base vs. Final Year..... 409

Figure 6 Global Market by Application Base Year..... 410

Figure 7 Global Market by Application Final Year ..... 411

Figure 8 Application Type Share by Year..... 412

Figure 9 by Application Segment Growth ..... 413

Figure 10 by Organism – Base vs. Final Year ..... 415

Figure 11 by Organism Market Base Year..... 416

Figure 12 by Organism Market Final Year ..... 417

Figure 13 by Organism Share by Year..... 418

Figure 14 by Organism Segment Growth ..... 419

Figure 15 Research Growth..... 422

Figure 16 Clinical Human Growth..... 424

Figure 17 Clinical Tumor Growth..... 426

Figure 18 Clinical Pathogen Growth ..... 428

Figure 19 Direct to Consumer Growth ..... 430

Figure 20 Agriculture/Other Growth..... 432

Figure 21 Human Growth ..... 435

Figure 22 Pathogen Growth..... 437

Figure 23 Other Organism Growth ..... 439